{"id":2945,"date":"2026-11-14T22:19:58","date_gmt":"2026-11-14T14:19:58","guid":{"rendered":"http:\/\/www.puriactives.com\/en\/?p=2945"},"modified":"2026-11-14T22:19:58","modified_gmt":"2026-11-14T14:19:58","slug":"puriactives-bioazelaic","status":"publish","type":"post","link":"http:\/\/www.puriactives.com\/en\/?p=2945","title":{"rendered":"PuriActives\u00ae BioAzelaic"},"content":{"rendered":"<p><main data-pm-slice=\"0 0 []\"><\/p>\n<section lang=\"zh-CN\">\n<section><\/section>\n<section>Product positioning<\/p>\n<h2>Skin and scalp care applications<\/h2>\n<p>Azelaic acid informs development for skin tone, blemish-prone skin, and redness, with preclinical leads for scalp applications.<\/p>\n<h3>01 \u00b7 Even skin tone and post-acne marks<\/h3>\n<p>Pigment-related enzyme mechanisms and randomized studies of melasma and post-inflammatory hyperpigmentation.<\/p>\n<h3>02 \u00b7 Blemish-prone skin<\/h3>\n<p>Keratinization, microbial, and inflammatory mechanisms, supported by vehicle-controlled clinical evidence.<\/p>\n<h3>03 \u00b7 Redness and skin comfort<\/h3>\n<p>KLK5\/cathelicidin mechanisms and rosacea studies inform formulations that prioritize tolerability.<\/p>\n<h3>04 \u00b7 Scalp and follicle research<\/h3>\n<p>5\u03b1-reductase, catalase, and Gli\/Shh findings provide preclinical research leads.<\/p>\n<section>43 \u00b7 Randomized controlled trials included in the 2023 systematic review<\/p>\n<p>20 rosacea \/ 16 acne \/ 7 melasma trials<\/p>\n<\/section>\n<p>[1] Todea et al., Polymers, 2021, DOI 10.3390\/polym13234091 \u2022 [2] King et al., J Cosmet Dermatol, 2023, DOI 10.1111\/jocd.15923<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Ingredient identity and biotechnology<\/p>\n<h2>Azelaic acid ingredient profile<\/h2>\n<p>Azelaic acid is a saturated nine-carbon dicarboxylic acid.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-full wp-image-2946\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/01_\u7b2c01\u8282_\u539f\u59cb\u56fe\u7247-2.png\" alt=\"\" width=\"300\" height=\"300\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/01_\u7b2c01\u8282_\u539f\u59cb\u56fe\u7247-2.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/01_\u7b2c01\u8282_\u539f\u59cb\u56fe\u7247-2-150x150.png 150w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Original 2D chemical structure \/ PubChem CID 2266<\/p>\n<table>\n<tbody>\n<tr>\n<th>\n<section>Property<\/section>\n<\/th>\n<th>\n<section>Ingredient information<\/section>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<section>INCI<\/section>\n<\/td>\n<td>\n<section>Azelaic Acid<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>IUPAC name<\/section>\n<\/td>\n<td>\n<section>Nonanedioic acid<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Molecular formula<\/section>\n<\/td>\n<td>\n<section>C\u2089H\u2081\u2086O\u2084<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Molecular weight<\/section>\n<\/td>\n<td>\n<section>188.22 g\/mol<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Salts and derivatives require separate assessment of identity, solubility, and efficacy. Their data are not directly interchangeable with azelaic acid data.<\/p>\n<p>[13] PubChem CID 2266, Azelaic Acid \u2022 Structure source: PubChem 2D conformer<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Ingredient identity and biotechnology<\/p>\n<h2>Biotechnological production<\/h2>\n<p>PuriActives\u00ae BioAzelaic is azelaic acid produced by a biotechnological process.<\/p>\n<p>Published research includes enzymatic and chemoenzymatic conversion of oleic-acid-derived intermediates. Production origin alone does not establish biological efficacy.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2947\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/02_\u7b2c04\u8282_\u539f\u59cb\u56fe\u7247-300x189.png\" alt=\"\" width=\"300\" height=\"189\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/02_\u7b2c04\u8282_\u539f\u59cb\u56fe\u7247-300x189.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/02_\u7b2c04\u8282_\u539f\u59cb\u56fe\u7247-1024x645.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/02_\u7b2c04\u8282_\u539f\u59cb\u56fe\u7247-768x484.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/02_\u7b2c04\u8282_\u539f\u59cb\u56fe\u7247.png 1148w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Published literature routes, rather than PuriPharm\u2019s proprietary production process.<\/p>\n<p>Published azelaic acid production routes; green arrows indicate enzymatic steps<\/p>\n<p>[1] Todea et al., Polymers, 2021, DOI 10.3390\/polym13234091 \u2022 Original Figure 1.<\/p>\n<p>The original scheme retains routes A\u2013F, enzyme names, intermediates, chemical structures, and cofactors H\u2082O, H\u2082O\u2082, NAD\u207a, NADPH, and O\u2082. Green arrows identify enzymatic steps.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Scientific basis<\/p>\n<h2>Mechanisms relevant to skin care<\/h2>\n<section>\n<h3>Azelaic acid: multiple biological pathways<\/h3>\n<\/section>\n<section>Pigment-related enzymes: tyrosinase and thioredoxin reductase<\/p>\n<\/section>\n<section>Keratinization: follicular and epidermal surface biology<\/p>\n<\/section>\n<section>Microbial activity: in vitro effects depend on concentration and pH<\/p>\n<\/section>\n<section>Inflammatory signaling: PPAR\u03b3, NF-\u03baB, and reactive oxygen species<\/p>\n<\/section>\n<section>Innate immunity: KLK5, cathelicidin, and serine protease activity<\/p>\n<\/section>\n<p>Finished-product claims require efficacy evidence for the relevant formulation.<\/p>\n<p>[3] Schallreuter and Wood, 1990, PMID 2114832 \u2022 [5] Blaskovich et al., 2019, DOI 10.1038\/s41598-019-50746-4 \u2022 [6] Coda et al., 2013, PMID 23871720 \u2022 [12] Feng et al., 2024, DOI 10.2147\/CCID.S485237<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin care evidence \/ Even skin tone<\/p>\n<h2>Pigment-related enzyme targets<\/h2>\n<p>Research reports that azelaic acid acts on tyrosinase and thioredoxin reductase.<\/p>\n<h3>Targets<\/h3>\n<h3>Melanin production<\/h3>\n<p>Tyrosinase regulates melanin synthesis. Ki describes the interaction in an isolated-enzyme assay.<\/p>\n<section>2.73 \u00d7 10\u207b\u00b3 M<\/p>\n<p>Ki for competitive inhibition of tyrosinase<\/p>\n<\/section>\n<h3>Epidermal redox biology<\/h3>\n<p>Thioredoxin reductase participates in epidermal redox processes. Visible skin tone and pigmentation benefits still require product evaluation.<\/p>\n<section>1.25 \u00d7 10\u207b\u2075 M<\/p>\n<p>Ki for inhibition of membrane-associated thioredoxin reductase<\/p>\n<\/section>\n<p>Enzyme inhibition constants do not directly demonstrate finished-product efficacy.<\/p>\n<p>[3] Schallreuter and Wood, Arch Dermatol Res, 1990, DOI 10.1007\/BF00372617; PMID 2114832<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin care evidence \/ Even skin tone<\/p>\n<h2>Clinical research in melasma<\/h2>\n<p>Seven randomized studies found that 20% azelaic acid outperformed vehicle for melasma severity and overall assessment.<\/p>\n<p>Proportion with good\/excellent improvement in one 24-week study<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2948\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/03_\u7b2c07\u8282_\u67f1\u72b6\u56fe_\u4e2d\u6587\u7248-300x136.png\" alt=\"\" width=\"300\" height=\"136\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/03_\u7b2c07\u8282_\u67f1\u72b6\u56fe_\u4e2d\u6587\u7248-300x136.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/03_\u7b2c07\u8282_\u67f1\u72b6\u56fe_\u4e2d\u6587\u7248-1024x465.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/03_\u7b2c07\u8282_\u67f1\u72b6\u56fe_\u4e2d\u6587\u7248-768x349.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/03_\u7b2c07\u8282_\u67f1\u72b6\u56fe_\u4e2d\u6587\u7248.png 1222w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<table>\n<tbody>\n<tr>\n<th>\n<section>Treatment<\/section>\n<\/th>\n<th>\n<section>Good\/excellent improvement<\/section>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<section>20% azelaic acid<\/section>\n<\/td>\n<td>\n<section>64.8%<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>4% hydroquinone<\/section>\n<\/td>\n<td>\n<section>72.5%<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Comparisons with 4% hydroquinone did not show a consistent significant difference. Interpret findings in the context of vehicle, duration, and outcome definitions.<\/p>\n<p>Results from a single controlled study. The systematic review found no consistent advantage of either treatment.<\/p>\n<p>[2] King et al., J Cosmet Dermatol, 2023, DOI 10.1111\/jocd.15923 \u2022 Systematic review including 7 melasma RCTs.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin care evidence \/ Even skin tone<\/p>\n<h2>A 12-week randomized study shows improvement in post-acne hyperpigmentation<\/h2>\n<p>60 participants \/ 20% azelaic acid cream \/ Twice daily \/ 12 weeks<\/p>\n<section>10.47 \u2192 7.00<\/p>\n<p>Within-group time effect: P &lt; 0.001<\/p>\n<p>Mean PAHI in the azelaic acid group: baseline to week 12<\/p>\n<\/section>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2949\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/04_\u7b2c08\u8282_\u539f\u59cb\u56fe\u7247-291x300.jpg\" alt=\"\" width=\"291\" height=\"300\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/04_\u7b2c08\u8282_\u539f\u59cb\u56fe\u7247-291x300.jpg 291w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/04_\u7b2c08\u8282_\u539f\u59cb\u56fe\u7247.jpg 538w\" sizes=\"(max-width: 291px) 100vw, 291px\" \/><\/section>\n<p>Post-acne hyperpigmentation index over time<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2950\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/05_\u7b2c08\u8282_\u539f\u59cb\u56fe\u7247-300x98.jpg\" alt=\"\" width=\"300\" height=\"98\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/05_\u7b2c08\u8282_\u539f\u59cb\u56fe\u7247-300x98.jpg 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/05_\u7b2c08\u8282_\u539f\u59cb\u56fe\u7247.jpg 605w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Representative azelaic acid participant photographs before and after treatment<\/p>\n<p>[4] Sobhan et al., J Res Med Sci, 2023, DOI 10.4103\/jrms.jrms_443_22 \u2022 Original Figures 2 and 3.<\/p>\n<p>Figure key: PAHI = post-acne hyperpigmentation index. The original azelaic acid and tranexamic acid curves and statistical annotations are retained.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin care evidence \/ Blemish-prone skin<\/p>\n<h2>Mechanisms relevant to blemish-prone skin<\/h2>\n<h3>01 \u00b7 Keratinization<\/h3>\n<p>Modulation of keratinocyte differentiation informs research on comedones and skin surface condition.<\/p>\n<h3>02 \u00b7 Microbial environment<\/h3>\n<p>In vitro activity requires relatively high concentrations and varies with assay conditions and pH.<\/p>\n<h3>03 \u00b7 Inflammatory signaling<\/h3>\n<p>Reactive oxygen species and inflammatory mediators are relevant targets in blemish-prone skin and redness research.<\/p>\n<h3>In vitro broth microdilution assay<\/h3>\n<section>8,000\u201316,000 \u00b5g\/mL \/ Representative azelaic acid MIC<\/p>\n<\/section>\n<p>In vitro antibacterial activity is weaker than that of antibiotics. Reported activity was greater at pH 5.6 than at pH 7.0.<\/p>\n<p>Evaluate microbial activity and cosmetic performance at the intended pH and under actual use conditions.<\/p>\n<p>[5] Blaskovich et al., Sci Rep, 2019, DOI 10.1038\/s41598-019-50746-4 \u2022 [12] Feng et al., 2024, DOI 10.2147\/CCID.S485237<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin care evidence \/ Blemish-prone skin<\/p>\n<h2>Comedone reduction in controlled studies<\/h2>\n<p>Four of 5 randomized studies reporting comedone outcomes found a clear difference between azelaic acid and vehicle.<\/p>\n<h3>Mean comedone reduction<\/h3>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2951\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/06_\u7b2c10\u8282_\u67f1\u72b6\u56fe_\u4e2d\u6587\u7248-300x136.png\" alt=\"\" width=\"300\" height=\"136\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/06_\u7b2c10\u8282_\u67f1\u72b6\u56fe_\u4e2d\u6587\u7248-300x136.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/06_\u7b2c10\u8282_\u67f1\u72b6\u56fe_\u4e2d\u6587\u7248-1024x465.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/06_\u7b2c10\u8282_\u67f1\u72b6\u56fe_\u4e2d\u6587\u7248-768x349.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/06_\u7b2c10\u8282_\u67f1\u72b6\u56fe_\u4e2d\u6587\u7248.png 1222w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<table>\n<tbody>\n<tr>\n<th>\n<section>Treatment<\/section>\n<\/th>\n<th>\n<section>Mean comedone reduction<\/section>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<section>20% azelaic acid<\/section>\n<\/td>\n<td>\n<section>70%<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Vehicle<\/section>\n<\/td>\n<td>\n<section>14%<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2952\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-300x51.jpg\" alt=\"\" width=\"300\" height=\"51\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-300x51.jpg 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-1024x175.jpg 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-768x131.jpg 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-1536x262.jpg 1536w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-2048x349.jpg 2048w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Good\/excellent overall improvement: 20% azelaic acid versus oral tetracycline, RR 0.97 [0.89\u20131.05], n = 594<\/p>\n<p>[2] King et al., J Cosmet Dermatol, 2023, DOI 10.1111\/jocd.15923 \u2022 Comedone analysis and original Figure 7.<\/p>\n<p>The forest plot retains events, sample sizes, weights, random-effects risk ratios, and 95% CIs. Left favors tetracycline; right favors azelaic acid.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin care evidence \/ Redness and comfort<\/p>\n<h2>Innate immunity and redness<\/h2>\n<table>\n<tbody>\n<tr>\n<th>\n<section>Research target<\/section>\n<\/th>\n<th>\n<section>Description<\/section>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<section>KLK5<\/section>\n<\/td>\n<td>\n<section>Kallikrein 5; serine protease activity<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>CAMP<\/section>\n<\/td>\n<td>\n<section>Cathelicidin expression<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>LL-37<\/section>\n<\/td>\n<td>\n<section>Downstream peptide biology<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Formulation evaluation<\/h3>\n<p>Visible redness, comfort, and tolerability require evaluation of the finished formula.<\/p>\n<p>In a 16-week open-label study, 15% azelaic acid gel was associated with reduced KLK5\/cathelicidin-related expression.<\/p>\n<p>Supporting models included cultured keratinocytes and mouse skin. Serine protease activity fell significantly in the subgroup with high baseline activity.<\/p>\n<p>[6] Coda et al., J Am Acad Dermatol, 2013, DOI 10.1016\/j.jaad.2013.05.019; PMID 23871720<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin care evidence \/ Redness and comfort<\/p>\n<h2>Clinical findings in rosacea<\/h2>\n<section>63% vs 48%<\/p>\n<p>Inflammatory lesion reduction at 12 weeks: azelaic acid versus vehicle<\/p>\n<\/section>\n<section>\u22122.82<\/p>\n<p>Pooled mean difference in inflammatory lesions [\u22123.64, \u22122.00]<\/p>\n<\/section>\n<section>RR 1.33<\/p>\n<p>Treatment success with 15% azelaic acid [1.19\u20131.48]; I\u00b2 = 0%<\/p>\n<\/section>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2954\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c12\u8282_\u539f\u59cb\u56fe\u7247-300x75.jpg\" alt=\"\" width=\"300\" height=\"75\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c12\u8282_\u539f\u59cb\u56fe\u7247-300x75.jpg 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c12\u8282_\u539f\u59cb\u56fe\u7247-1024x255.jpg 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c12\u8282_\u539f\u59cb\u56fe\u7247-768x191.jpg 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c12\u8282_\u539f\u59cb\u56fe\u7247-1536x382.jpg 1536w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c12\u8282_\u539f\u59cb\u56fe\u7247-2048x510.jpg 2048w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Treatment success, 5 RCTs, n = 2,905<\/p>\n<p>[2] King et al., J Cosmet Dermatol, 2023, DOI 10.1111\/jocd.15923 \u2022 Original Figure 6 and pooled lesion analysis.<\/p>\n<p>The forest plot retains all five trials and the pooled result. Left favors vehicle; right favors azelaic acid.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin care evidence \/ Redness and comfort<\/p>\n<h2>Tolerability and formulation design<\/h2>\n<h3>Application reactions in clinical studies<\/h3>\n<p>Early use may cause itching, burning, or stinging. Dryness and erythema can affect comfort during repeated use. In the PAHI study, early erythema and burning were reported more often in the azelaic acid group.<\/p>\n<h3>Formulation priorities<\/h3>\n<p>Screen vehicle, pH, and physical form together. Assess stinging, dryness, and after-feel during early and repeated use. Address both barrier support and comfort.<\/p>\n<p>[2] King et al., 2023, DOI 10.1111\/jocd.15923 \u2022 [4] Sobhan et al., 2023, DOI 10.4103\/jrms.jrms_443_22<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Scalp and hair research<\/p>\n<h2>In vitro inhibition of 5\u03b1-reductase<\/h2>\n<p>An in vitro human skin study found concentration-dependent inhibition of 5\u03b1-reductase activity by azelaic acid.<\/p>\n<h3>Experimental system<\/h3>\n<p>In vitro human skin preparation; 1,2-[\u00b3H]-testosterone substrate; 5\u03b1-reductase activity outcome; azelaic acid concentration series.<\/p>\n<section>0.2 mmol\/L<\/p>\n<p>Concentration at which inhibition was detectable<\/p>\n<\/section>\n<section>3 mmol\/L<\/p>\n<p>Concentration producing complete inhibition in the assay<\/p>\n<\/section>\n<h3>Application validation<\/h3>\n<p>In vitro enzyme inhibition does not establish hair-growth or anti-hair-loss efficacy in humans.<\/p>\n<p>Validate follicular models before assessing predefined human scalp outcomes.<\/p>\n<p>[8] Stamatiadis et al., Br J Dermatol, 1988, DOI 10.1111\/j.1365-2133.1988.tb03474.x; PMID 3207614<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Scalp and hair research<\/p>\n<h2>Catalase responses in follicular cells<\/h2>\n<p>The catalase response to azelaic acid was cell-type-specific in mouse follicular cells.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2955\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/10_\u7b2c15\u8282_\u539f\u59cb\u56fe\u7247-300x247.jpg\" alt=\"\" width=\"300\" height=\"247\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/10_\u7b2c15\u8282_\u539f\u59cb\u56fe\u7247-300x247.jpg 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/10_\u7b2c15\u8282_\u539f\u59cb\u56fe\u7247.jpg 716w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>A: bulge cells; B: bulge cells; C: bulb cells; D: bulb cells<\/p>\n<p>Bulge cells: significantly higher catalase activity. Bulb cells: no significant change. Azelaic acid 2.5 or 25 mM; UVB 20 mJ\/cm\u00b2. Mouse vibrissa follicular cell system.<\/p>\n<p>Preclinical findings do not directly establish cosmetic efficacy in humans.<\/p>\n<p>Catalase activity in follicle-derived cells \/ Original Figure 1.<\/p>\n<p>[7] Amirfakhryan et al., Avicenna J Phytomed, 2020;10:460\u2013471; PMID 32995324 \u2022 Original Figure 1.<\/p>\n<p>Original axes: catalase activity (%) and time (seconds). Control, UVB, azelaic acid concentrations, combined conditions, error bars, and statistical annotations are retained.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Scalp and hair research<\/p>\n<h2>Gli and Shh responses in follicular models<\/h2>\n<p>Azelaic acid upregulated Gli transcripts, while the Shh protein response depended on the presence of minoxidil.<\/p>\n<section>194.81-fold<\/p>\n<p>Gli1 mRNA after 25 mM azelaic acid<\/p>\n<\/section>\n<section>10.82-fold<\/p>\n<p>Gli2 mRNA after 25 mM azelaic acid<\/p>\n<\/section>\n<p>Single-agent transcription findings \/ Mouse follicle-derived cells<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2956\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/11_\u7b2c16\u8282_\u539f\u59cb\u56fe\u7247-300x99.jpg\" alt=\"\" width=\"300\" height=\"99\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/11_\u7b2c16\u8282_\u539f\u59cb\u56fe\u7247-300x99.jpg 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/11_\u7b2c16\u8282_\u539f\u59cb\u56fe\u7247.jpg 710w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Shh-positive bulb and bulge cells \/ Quantification panels from original Figure 2.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2957\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/12_\u7b2c16\u8282_\u539f\u59cb\u56fe\u7247-2-300x182.jpg\" alt=\"\" width=\"300\" height=\"182\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/12_\u7b2c16\u8282_\u539f\u59cb\u56fe\u7247-2-300x182.jpg 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/12_\u7b2c16\u8282_\u539f\u59cb\u56fe\u7247-2.jpg 713w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Shh intensity in follicular organ culture \/ Quantification panel from original Figure 3.<\/p>\n<p>[7] Amirfakhryan et al., 2020, PMID 32995324 \u2022 Quantification panels from original Figures 2 and 3.<\/p>\n<p>The original concentration labels, single and combination treatments, Shh-positive cell percentages, Shh intensity, and statistical symbols are retained.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Scalp and hair research<\/p>\n<h2>Scalp product development and validation<\/h2>\n<table>\n<tbody>\n<tr>\n<th>\n<section>Development question<\/section>\n<\/th>\n<th>\n<section>Targeted measurements<\/section>\n<\/th>\n<th>\n<section>Role of current evidence<\/section>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<section>Scalp comfort and appearance<\/section>\n<\/td>\n<td>\n<section>Grading of itching, visible redness, greasiness, and dandruff<\/section>\n<\/td>\n<td>\n<section>Define human cosmetic evaluation outcomes<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Follicular delivery<\/section>\n<\/td>\n<td>\n<section>Ex vivo deposition and release under relevant conditions<\/section>\n<\/td>\n<td>\n<section>Microemulsion research informs carrier design<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Follicular biology<\/section>\n<\/td>\n<td>\n<section>Catalase, Gli\/Shh, and androgen-related experimental systems<\/section>\n<\/td>\n<td>\n<section>Generate preclinical hypotheses<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Hair-fiber performance<\/section>\n<\/td>\n<td>\n<section>Combing, breakage, and mechanical testing<\/section>\n<\/td>\n<td>\n<section>Requires separate hair-fiber experiments<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Human hair-growth claims and hair-fiber care benefits require separate, targeted validation.<\/p>\n<p>[7] Amirfakhryan et al., 2020, PMID 32995324 \u2022 [11] Salimi et al., 2020, DOI 10.34172\/apb.2020.028<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Formulation science<\/p>\n<h2>Solubility and physical form<\/h2>\n<section>4.5 \/ 5.3<\/p>\n<p>Reported pKa values for the two carboxyl groups<\/p>\n<\/section>\n<section>\u22480.24% w\/w<\/p>\n<p>Upper water-solubility value reported in the patent background<\/p>\n<\/section>\n<h3>Two formulation routes<\/h3>\n<h3>Dissolved systems<\/h3>\n<p>Screen glycol\u2013water ratios, ionization, and recrystallization risk at the target pH and over the intended storage range.<\/p>\n<h3>Solid dispersions<\/h3>\n<p>Control particle size, sedimentation, redispersibility, grittiness, and release. Confirm that the rheology stabilizes the chosen physical form.<\/p>\n<p>Ionization, solvent composition, and solid-state behavior affect delivery and user experience.<\/p>\n<p>After selecting a dissolved or dispersed system, optimize rheology, sensory properties, and packaging.<\/p>\n<p>[9] US5925679, 1999 \u2022 [12] Feng et al., 2024, DOI 10.2147\/CCID.S485237 \u2022 [14] Li et al., 2012, PMID 22111946<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Formulation science<\/p>\n<h2>Glycol\u2013water ratios for solubilization<\/h2>\n<table>\n<tbody>\n<tr>\n<th>\n<section>Glycol system<\/section>\n<\/th>\n<th>\n<section>Glycol<\/section>\n<\/th>\n<th>\n<section>Water<\/section>\n<\/th>\n<th>\n<section>AzA<\/section>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<section>Propylene glycol<\/section>\n<\/td>\n<td>\n<section>45%<\/section>\n<\/td>\n<td>\n<section>40%<\/section>\n<\/td>\n<td>\n<section>1.10%<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Dipropylene glycol<\/section>\n<\/td>\n<td>\n<section>30%<\/section>\n<\/td>\n<td>\n<section>45%<\/section>\n<\/td>\n<td>\n<section>1.10%<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Butylene glycol<\/section>\n<\/td>\n<td>\n<section>35%<\/section>\n<\/td>\n<td>\n<section>45%<\/section>\n<\/td>\n<td>\n<section>1.10%<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>PEG-32<\/section>\n<\/td>\n<td>\n<section>30%<\/section>\n<\/td>\n<td>\n<section>40%<\/section>\n<\/td>\n<td>\n<section>1.10%<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Ethoxydiglycol<\/section>\n<\/td>\n<td>\n<section>25%<\/section>\n<\/td>\n<td>\n<section>50%<\/section>\n<\/td>\n<td>\n<section>1.10%<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Hexylene glycol<\/section>\n<\/td>\n<td>\n<section>20%<\/section>\n<\/td>\n<td>\n<section>45%<\/section>\n<\/td>\n<td>\n<section>1.10%<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Formulation priorities<\/h3>\n<p>Solubilizing capacity varies among glycols. Adding water may lower azelaic acid solubility in these systems. Screen glycol\u2013water ratios experimentally.<\/p>\n<p>Map solubility and verify recrystallization risk and storage stability.<\/p>\n<p>Selected patent combinations, each containing 1.10% azelaic acid \/ Data from Table 1.<\/p>\n<p>[9] US5925679, Topical vehicles containing solubilized and stabilized azelaic acid, 1999 \u2022 Data from Table 1.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Formulation science<\/p>\n<h2>Controlled clinical study of a nanocrystal hydrogel<\/h2>\n<p>In an 8-week randomized study, one specific 10% azelaic acid nanocrystal hydrogel had similar efficacy to a 20% cream.<\/p>\n<h3>Lesion reduction at week 8<\/h3>\n<table>\n<tbody>\n<tr>\n<th>\n<section>Lesions<\/section>\n<\/th>\n<th>\n<section>10% nanocrystal gel<\/section>\n<\/th>\n<th>\n<section>20% cream<\/section>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<section>Inflammatory lesions<\/section>\n<\/td>\n<td>\n<section>39.15%<\/section>\n<\/td>\n<td>\n<section>33.76%<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Non-inflammatory lesions<\/section>\n<\/td>\n<td>\n<section>34.58%<\/section>\n<\/td>\n<td>\n<section>27.96%<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>39.15% vs 33.76%<\/p>\n<p>10% nanocrystal gel \/ 20% cream<\/p>\n<p>34.58% vs 27.96%<\/p>\n<p>Both groups improved over time, p &lt; 0.001; efficacy was similar between groups.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2958\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/13_\u7b2c20\u8282_\u539f\u59cb\u56fe\u7247-300x109.jpg\" alt=\"\" width=\"300\" height=\"109\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/13_\u7b2c20\u8282_\u539f\u59cb\u56fe\u7247-300x109.jpg 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/13_\u7b2c20\u8282_\u539f\u59cb\u56fe\u7247.jpg 768w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>10% azelaic acid nanocrystal hydrogel: baseline, week 4, and week 8 \/ Original Figure 3.<\/p>\n<p>[10] Tomi\u0107 et al., Pharmaceutics, 2021, DOI 10.3390\/pharmaceutics13040567 \u2022 Original Figure 3.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Formulation science<\/p>\n<h2>Microemulsions and follicular delivery<\/h2>\n<section>48\u2013151 nm<\/p>\n<p>Droplet-size range across 8 systems<\/p>\n<\/section>\n<section>36\u201342%<\/p>\n<p>Cumulative release at 24 hours<\/p>\n<\/section>\n<p>Ex vivo guinea pig skin: all 8 microemulsions increased flux relative to an aqueous solution.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2959\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/14_\u7b2c21\u8282_\u539f\u59cb\u56fe\u7247-300x139.jpg\" alt=\"\" width=\"300\" height=\"139\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/14_\u7b2c21\u8282_\u539f\u59cb\u56fe\u7247-300x139.jpg 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/14_\u7b2c21\u8282_\u539f\u59cb\u56fe\u7247-768x356.jpg 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/14_\u7b2c21\u8282_\u539f\u59cb\u56fe\u7247.jpg 957w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Cumulative release from 8 microemulsions containing 1% azelaic acid \/ Original release plot.<\/p>\n<p>Carrier composition affects azelaic acid release and skin transport.<\/p>\n<p>[11] Salimi et al., Adv Pharm Bull, 2020, DOI 10.34172\/apb.2020.028 \u2022 Original release plot.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Product application concepts<\/p>\n<h2>Product application options<\/h2>\n<table>\n<tbody>\n<tr>\n<th>\n<section>Product concept<\/section>\n<\/th>\n<th>\n<section>Format<\/section>\n<\/th>\n<th>\n<section>Ingredient rationale<\/section>\n<\/th>\n<th>\n<section>Development priorities<\/section>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<section>Tone-evening serum<\/section>\n<\/td>\n<td>\n<section>Dissolved or finely dispersed serum<\/section>\n<\/td>\n<td>\n<section>Skin tone and post-acne mark research<\/section>\n<\/td>\n<td>\n<section>Recrystallization, color uniformity, and visible skin tone outcomes<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Clear-skin gel cream<\/section>\n<\/td>\n<td>\n<section>Low-grit gel cream or lotion<\/section>\n<\/td>\n<td>\n<section>Keratinization and blemish-prone skin<\/section>\n<\/td>\n<td>\n<section>Particle control, early comfort, and lesion appearance<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Redness-soothing lotion<\/section>\n<\/td>\n<td>\n<section>Barrier-supporting leave-on lotion<\/section>\n<\/td>\n<td>\n<section>Innate immunity and redness research<\/section>\n<\/td>\n<td>\n<section>Stinging, dryness, visible redness, and repeat-use tolerability<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Leave-on scalp serum<\/section>\n<\/td>\n<td>\n<section>Lightweight emulsion or delivery-focused liquid<\/section>\n<\/td>\n<td>\n<section>Follicular biology and scalp care<\/section>\n<\/td>\n<td>\n<section>Deposition, residue, greasiness, dandruff, and comfort<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>[2], [4], [6]\u2013[12] \u2022 Each formula requires stability, compatibility, and efficacy validation.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>References<\/p>\n<h2>References and technical sources<\/h2>\n<p>[1] Todea A et al. Azelaic Acid: A Bio-Based Building Block for Biodegradable Polymers. Polymers. 2021;13:4091. doi:10.3390\/polym13234091<\/p>\n<p>[2] King S et al. A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging. J Cosmet Dermatol. 2023;22:2650\u20132662. doi:10.1111\/jocd.15923<\/p>\n<p>[3] Schallreuter KU, Wood JM. A possible mechanism of action for azelaic acid in the human epidermis. Arch Dermatol Res. 1990;282:168\u2013171. doi:10.1007\/BF00372617<\/p>\n<p>[4] Sobhan M et al. A comparative study of 20% azelaic acid cream versus 5% tranexamic acid solution for postinflammatory hyperpigmentation. J Res Med Sci. 2023;28:18. doi:10.4103\/jrms.jrms_443_22<\/p>\n<p>[5] Blaskovich MAT et al. In vitro Antimicrobial Activity of Acne Drugs Against Skin-Associated Bacteria. Sci Rep. 2019;9:14658. doi:10.1038\/s41598-019-50746-4<\/p>\n<p>[6] Coda AB et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69:570\u2013577. doi:10.1016\/j.jaad.2013.05.019<\/p>\n<p>[7] Amirfakhryan E et al. Azelaic acid stimulates catalase activation and promotes hair growth through upregulation of Gli1 and Gli2 mRNA and Shh protein. Avicenna J Phytomed. 2020;10:460\u2013471. PMID:32995324<\/p>\n<p>[8] Stamatiadis D et al. Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988;119:627\u2013632. doi:10.1111\/j.1365-2133.1988.tb03474.x<\/p>\n<p>[9] Mather K, Stahl CR. Topical vehicles containing solubilized and stabilized azelaic acid. US5925679. 1999. Table 1 and specification.<\/p>\n<p>[10] Tomi\u0107 I et al. Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris. Pharmaceutics. 2021;13:567. doi:10.3390\/pharmaceutics13040567<\/p>\n<p>[11] Salimi A et al. Development and Evaluation of Azelaic Acid-Loaded Microemulsion for Transfollicular Drug Delivery Through Guinea Pig Skin. Adv Pharm Bull. 2020;10:239\u2013246. doi:10.34172\/apb.2020.028<\/p>\n<p>[12] Feng X et al. Azelaic Acid: Mechanisms of Action and Clinical Applications. Clin Cosmet Investig Dermatol. 2024. doi:10.2147\/CCID.S485237<\/p>\n<p>[13] PubChem. Azelaic Acid, CID 2266. Molecular formula, molecular weight, IUPAC name and 2D chemical structure. National Library of Medicine.<\/p>\n<p>[14] Li N et al. Effect of ionization and vehicle on skin absorption and penetration of azelaic acid. Drug Dev Ind Pharm. 2012. doi:10.3109\/03639045.2011.635376<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<\/section>\n<p><\/main><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Product positioning Skin and scalp care applications Az [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[],"_links":{"self":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2945"}],"collection":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2945"}],"version-history":[{"count":1,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2945\/revisions"}],"predecessor-version":[{"id":2965,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2945\/revisions\/2965"}],"wp:attachment":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2945"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}